Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer
Open Access
- 3 March 2022
- journal article
- research article
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (1) , 115-121
Abstract
The purpose of the study: to conduct a systematic literature review on the effectiveness and feasibility of using information on the presence of KRAS gene mutations (in different codons), TP 53 (KP), ST K11/LKB1 (KL), and KEAP mutations and the association of KRAS m with PD -L1 status in patients with non-small cell lung cancer (NSCLC ) as a predictor of the effectiveness of immunotherapy with immune checkpoint inhibitors.Material and Methods. The review includes data from randomized clinical trials and meta-analyses on the predictive value of KRAS mutation status for response to immunotherapy in patients with NSCLC over the past 10 years.Results. The presence of KRAS mutations in NSCLC patients could be a predictive factor for their response to immunotherapy, as several studies have demonstrated benefit from immunotherapy in these patients. The combination of KRAS mutation with TP 53 (KP) co-mutation predicts a better response to immunotherapy, while a combination with ST K11/LKB1 (KL) and KEAP 1 predicts a worse response (reduced response rate and overall and disease-free survival). In PD -L1-positive patients, the presence of KRAS mutation is associated with a better prognosis after treatment with immunotherapy. Moreover, the presence of KRAS mutation is associated with a worse response to first-line and subsequent-line chemotherapy, thus indicating a more promising use of immunotherapy in these patients.Conclusion. Identification of TP 53 (KP), ST K11/LKB1 (KL), and KEAP 1 co-mutations and the presence of KRAS mutation in addition to determination PD -L expression enable selection of patients who will obtain the greatest benefit from immunotherapy. In addition, the ability to determine KRAS mutation and co-mutation status using a liquid biopsy (with acceptable specificity and sensitivity) makes it possible to use this method for determining sensitivity to immunotherapy when it is not possible to obtain tumor sample (to determine PD 1-L1 expression).Keywords
This publication has 27 references indexed in Scilit:
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung AdenocarcinomaClinical Cancer Research, 2017
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung CancerJAMA Oncology, 2016
- Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applicationsExpert Review of Respiratory Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyOncotarget, 2015
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCancer Discovery, 2015
- Variability in the Treatment of Elderly Patients with Stage IIIA (N2) Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- RAS Interaction with PI3K: More Than Just Another Effector PathwayGenes & Cancer, 2011
- Clinical Relevance of KRAS in Human CancersJournal of Biomedicine and Biotechnology, 2010
- KRAS Mutations in Non-Small Cell Lung CancerProceedings of the American Thoracic Society, 2009